Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Lexeo Therapeutics, Inc. (LXEO)

Lexeo Therapeutics agrees to buy Mantle Therapeutics for $8.3 million upfront

Neutral Impact 4 of 5 m&a Written later

Lexeo Therapeutics signed a merger agreement on September 16, 2026, to acquire private clinical-stage company Mantle Therapeutics, paying $8.3 million upfront in cash and stock, with up to $13.0 million more in contingent payments. The company also announced three research collaborations on cerebellar-targeted frataxin gene therapy and said cash runway guidance into 2028 is unchanged.

Key points

  • Upfront consideration: $5.3 million in cash, subject to adjustments, and $3.0 million in Lexeo common stock
  • Contingent payments: an additional $1.0 million in cash and up to $12.0 million in milestones, none guaranteed; total potential consideration is $21.3 million per the press release
  • Closing requires Requisite Stockholder Approval; Key Stockholders holding about 76.1% of Mantle capital stock agreed to support the deal; either party may terminate if the merger is not completed by November 16, 2026
  • The press release expects closing in the third quarter of 2026 and states the deal is funded within existing balance sheet capacity

The filing

CompanyLexeo Therapeutics, Inc. (LXEO)
Form8-K, current report
Filed with the SECSep 22, 2026, 7:08 AM ET
Accession number0001193125-26-397221

Items reported: 1.01 Material Definitive Agreement8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 22, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.